AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.
With an aim to build a pipeline of five assets by 2020, AUM Biosciences will in-license assets from academia and industry partners with a focus on small molecules. AUM Biosciences is led by a highly-experienced management team with more than 50 years of high-quality oncology drug development experience combined. Headquartered in Singapore, AUM Biosciences is strategically positioned to work with leading research centres throughout Asia.
AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need.